Differential Plasma Proteins Identified via iTRAQ-Based Analysis Serve as Diagnostic Markers of Pancreatic Ductal Adenocarcinoma

• Published in: Disease markers Vol. 2023; pp. 5145152 - 11
• Main Authors: Chen, Xiubing, Liao, Xiaomin, Zheng, Biaolin, Wang, Feng, Chen, Feiran, Deng, Zhejun, Jiang, Haixing, Qin, Shanyu
• Format: Journal Article
• Language: English
• Published: United States Hindawi 2023; Hindawi Limited
• Subjects: Adenocarcinoma; Antigens; Biomarkers; Biomarkers, Tumor - metabolism; Biotechnology; Blood Proteins; Body mass index; CA-19-9 Antigen; Cancer; Carbohydrates; Carcinoma, Pancreatic Ductal - diagnosis; Carcinoma, Pancreatic Ductal - pathology; Diagnostic systems; Enzyme-linked immunosorbent assay; Growth factors; GTP-binding protein; Hemoglobin; Humans; Immunoglobulins; Insulin; Insulin-like growth factor-binding protein 2; Laboratories; Mass spectrometry; Pancreatic cancer; Pancreatic Neoplasms; Pancreatic Neoplasms - pathology; Peptides; Peroxiredoxin; Plasma; Plasma proteins; Proteins; Scientific imaging; Sialyl Lewis a antigen; Software; Beijing China; United States > US; Massachusetts; China
• ISSN: 0278-0240; 1875-8630
• DOI: 10.1155/2023/5145152

Objective. We aimed to identify differentially expressed proteins in the plasma of patients with pancreatic cancer and control subjects, which could serve as potential tumor biomarkers. Methods. Differentially expressed proteins were determined via isostatic labeling and absolute quantification (iTRAQ). Potential protein biomarkers were identified via enzyme-linked immunosorbent assay (ELISA) in 40 patients and 40 control subjects, and those eventually selected were further validated in 40 pancreatic cancer and normal pancreatic tissues. Results. In total, 30 proteins displayed significant differences in expression among which 21 were downregulated and 9 were upregulated compared with the control group. ELISA revealed downregulation of peroxiredoxin-2 (PRDX2) and upregulation of alpha-1-antitrypsin (AAT), Ras-related protein Rab-2B (RAB2B), insulin-like growth factor-binding protein 2 (IGFBP2), Rho-related GTP-binding protein RhoC (RHOC), and prelamin-A/C (LMNA) proteins in 40 other samples of pancreatic cancer. Notably, only AAT, RAB2B, and IGFBP2 levels were consistent with expression patterns obtained with iTRAQ. Moreover, all three proteins displayed a marked increase in pancreatic cancer tissues. Data from ROC curve analysis indicated that the diagnostic ability of AAT, RAB2B, and IGFBP2 combined with carbohydrate antigen 19-9 (CA19-9) for pancreatic cancer was significantly greater than that of the single indexes (area under the curve (AUC): 90% vs. 75% (CA19-9), 76% (AAT), 71% (RAB2B), and 71% (IGFBP2), all P<0.01). Conclusion. AAT, RAB2B, and IGFBP2 could serve as effective biomarkers to facilitate the early diagnosis of pancreatic cancer.